Psychedelic Use Outside the Clinic and How Brain Immune Cells Contain Plaques
UCSF opens CANOPY, a large observational study of psychedelic use in everyday settings. UVA’s new coverage revisits an October mouse study on CASS4. A dated NOAA space weather update follows.
UCSF release · 10 November 2026 · Observational study launch
UCSF Opens a Study of Psychedelic Use in Everyday Settings
UCSF is enrolling people already planning to use psychedelics in everyday settings. The study aims to follow up to 3,000 people before use and for up to six months afterwards. Some participants will contribute brain imaging, EEG and wearable measurements.
Observation: The study launch and enrolment are documented. ARPA-H’s CANOPY award began on 21 September 2026 and is worth up to US$1.4 million. No outcomes have been reported in the launch sources.
Interpretation: Prospective measurement can establish timing, but does not remove selection or confounding.
Hypothesis: Context or baseline characteristics may predict differences in reported outcomes.
Testimony: No participant results or testimony reported in these sources.
Speculation: Efficacy, safety and generalisability beyond the cohort have not been demonstrated.
Unresolved: Recruitment mix, missing data, substance and dose verification, adjustment for expectancy and setting and eventual independent replication.
Why It Matters: Outcomes in ordinary settings and methods for studying set and setting.
Paper first published online 27 October 2026 · UVA coverage 10 November 2026
CASS4 and Amyloid Plaques in a Mouse Model
Deleting Cass4 in a mouse model of Alzheimer’s disease reduced the ability of microglia, the brain’s resident immune cells, to respond to and compact amyloid plaques.
Observation: Whole-body deletion also worsened measured cognitive flexibility in the mice. Human genetic evidence links CASS4 to Alzheimer’s risk through association.
Interpretation: Microglial response is one plausible path linking CASS4 to amyloid pathology.
Hypothesis: CASS4-related pathways might be useful research targets.
Testimony: The release includes researcher commentary; evidence rests on the experiments.
Speculation: Claims of a diagnostic or treatment benefit in people are premature.
Unresolved: Independent replication, relevance to human disease and whether changing the pathway helps safely.
Why It Matters: Immune mechanisms affecting brain function and cognition.